2020 FDA Approvals: A Year in Review by Lara Frick March 15, 2021CDER, Center for Drug Evaluation and Research, FDA, FDA Approvals, Food and Drug Administration, Magellan Health, Magellan RX, Magellan Rx Management, New Drugs, Novel agents, Novel drugs, Orphan Drugs
2019 FDA Approvals: A Year in Review by Lara Frick March 19, 2020Biosimilairs, FDA, FDA Approvals, Magellan Health, Magellan RX, Magellan Rx Management, New Drugs, Novel drugs, Orphan Drugs, Trend Alert
Trend Alert: FDA Approvals – A Year in Review by Lara Frick March 22, 2019Biosimilars, FDA, FDA Approvals, Magellan, Magellan Health, Magellan Healthcare, Magellan RX, Magellan Rx Management, New Drug Therapy Approvals, Novel drugs, Orphan Drugs, Rare Diseases
MRx Pipeline by Maryam Tabatabai November 30, 2018Biosimilars, Drug Pipeline, Emerging therapeutics, FDA, Magellan, Magellan Health, Magellan RX, Magellan Rx Management, MRx Pipeline, Orphan Drugs, Specialty Medications
